PT Kalbe Farma Tbk. (KLBF.JK)
- Previous Close
1,595.00 - Open
1,590.00 - Bid 1,990.00 x --
- Ask 1,200.00 x --
- Day's Range
1,555.00 - 1,605.00 - 52 Week Range
1,375.00 - 2,100.00 - Volume
26,347,800 - Avg. Volume
38,526,309 - Market Cap (intraday)
71.927T - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
25.06 - EPS (TTM)
62.05 - Earnings Date Aug 2, 2024 - Aug 3, 2024
- Forward Dividend & Yield 31.00 (1.94%)
- Ex-Dividend Date May 29, 2024
- 1y Target Est
1,663.60
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
www.kalbe.co.id13,062
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: KLBF.JK
Performance Overview: KLBF.JK
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KLBF.JK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KLBF.JK
Valuation Measures
Market Cap
73.78T
Enterprise Value
70.24T
Trailing P/E
25.68
Forward P/E
22.83
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.38
Price/Book (mrq)
3.30
Enterprise Value/Revenue
2.27
Enterprise Value/EBITDA
16.76
Financial Highlights
Profitability and Income Statement
Profit Margin
9.27%
Return on Assets (ttm)
8.24%
Return on Equity (ttm)
12.38%
Revenue (ttm)
30.94T
Net Income Avi to Common (ttm)
2.87T
Diluted EPS (ttm)
62.05
Balance Sheet and Cash Flow
Total Cash (mrq)
4.23T
Total Debt/Equity (mrq)
2.90%
Levered Free Cash Flow (ttm)
2.19T